Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Cryo-Cell International's Revenue for the
three
months ended in May. 2026 was €6.66 Mil. Cryo-Cell International's average Accounts Receivable for the
three
months ended in May. 2026 was €5.84 Mil.
Hence, Cryo-Cell International's Receivables Turnover for the
three
months ended in May. 2026 was 1.14.
Cryo-Cell International (FRA:ZCY) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Cryo-Cell International Receivables Turnover Related Terms
Cryo-Cell International Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Cryo-Cell International's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cryo-Cell International Receivables Turnover Chart
FRA:ZCY vs EHSI, PIII, CCM: Receivables Turnover Comparison
For the Medical Care Facilities subindustry, Cryo-Cell International's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryo-Cell International Receivables Turnover vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Cryo-Cell International's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cryo-Cell International (FRA:ZCY) has a Receivables Turnover of 1.14 as of May. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Cryo-Cell International and its competitors. According to the industry distribution chart, Cryo-Cell International ranks #502 out of 657 companies in the Healthcare Providers & Services industry, placing it in the top 76.4%.
Is Cryo-Cell International's Receivables Turnover too high?
Cryo-Cell International's current Receivables Turnover is 1.14. The Healthcare Providers & Services industry median Receivables Turnover is 7.74. Cryo-Cell International's value of 1.14 is 85.3% below this industry median. Based on the distribution chart, Cryo-Cell International ranks #502 out of 657 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Cryo-Cell International has a GF Score™ of 58/100, reflecting its overall financial health beyond just this single metric.
How does Cryo-Cell International's Receivables Turnover compare to EHSI and PIII?
According to the Healthcare Providers & Services industry distribution chart, Cryo-Cell International ranks #502 out of 657 companies for Receivables Turnover. This places Cryo-Cell International in the lower half of its industry. The industry median Receivables Turnover is 7.74. Cryo-Cell International's value of 1.14 is 85.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Healthcare Providers & Services company?
The median Receivables Turnover among Healthcare Providers & Services companies is 7.74, based on 657 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cryo-Cell International's current Receivables Turnover of 1.14 is 85.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Cryo-Cell International and its competitors. For the Healthcare Providers & Services industry, the median Receivables Turnover is 7.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cryo-Cell International's current Receivables Turnover is 1.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryo-Cell International stock overvalued right now?
Cryo-Cell International (FRA:ZCY) has a current Receivables Turnover of 1.14. The stock's GF Value™ is €4.29, compared to a current price of €2.74 — trading 36.1% below its estimated fair value. The current Receivables Turnover is 1.14 and 85.3% below the Healthcare Providers & Services industry median of 7.74. Cryo-Cell International's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Cryo-Cell International (FRA:ZCY), the current Receivables Turnover is 1.14 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryo-Cell International (FRA:ZCY) Overvalued in 2026?
Based on GuruFocus' analysis, Cryo-Cell International stock appears to be undervalued.
The current stock price of €2.74 is trading 36.1% below its estimated GF Value™ of €4.29.
Key valuation signals for FRA:ZCY:
Receivables Turnover: 1.14
GF Value™: €4.29 vs. price of €2.74 (36.1% below fair value)
Industry Position: 85.3% below the Healthcare Providers & Services median (#502 of 657)
No single metric tells the full story. See the FRA:ZCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
58GF Score
Get the complete analysis for FRA:ZCY
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ZCY has been successfully added to your 
